Severe Hypertriglyceridemia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, and Others

The report titled "Severe Hypertriglyceridemia Pipeline Insight 2023" by DelveInsight offers extensive information on more than 10+ companies and 10+ pipeline drugs in the field of Severe Hypertriglyceridemia. It presents detailed profiles of these drugs, encompassing both Severe Hypertriglyceridemia clinical trials and nonclinical stage products. The Severe Hypertriglyceridemia pipeline report also includes a thorough assessment of therapeutics based on product type, stage, route of administration, and molecule type. Additionally, it highlights the inactive pipeline products in this area.

The Severe Hypertriglyceridemia Pipeline report provides an elaborate account of the drug, encompassing its mechanism of action, Severe Hypertriglyceridemia clinical trials studies, Severe Hypertriglyceridemia NDA approvals (if any), and product development endeavors such as technology advancements, collaborations pertaining to Severe Hypertriglyceridemia, licensing, mergers and acquisitions, funding, designations, and other relevant details concerning the product.

To explore more information on the latest breakthroughs in the Severe Hypertriglyceridemia Pipeline treatment landscape of the report, click here @ Severe Hypertriglyceridemia Pipeline Outlook- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report
• Over 10+ Severe Hypertriglyceridemia companies are evaluating 10+ Severe Hypertriglyceridemia pipeline therapies in various stages of development, and their anticipated acceptance in the Severe Hypertriglyceridemia market would significantly increase market revenue.
• The leading Severe Hypertriglyceridemia companies are working in the market such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
• Promising Severe Hypertriglyceridemia Pipeline Therapies in various stages of development include Pegozafermin, Olezarsen, Ethyl Icosapentate, K-877, Fenofibrate, omefas, CaPre, and others
• Regeneron Pharmaceuticals' evinacumab was approved under the brand name Evkeeza by FDA in February 2021 for homozygous familial hypercholesterolemia. Regeneron Pharmaceuticals' Evinacumab (also known as REGN1500) is an intravenous ANGPTL-3 Antibody. A recent Phase II trial showed monoclonal antibody evinacumab significantly reduced fasting triglycerides in patients with severe hypertriglyceridemia with acute pancreatitis. Evinacumab binds to angiopoietin-like protein 3 (ANGPTL3), a protein thought to play a role in cholesterol metabolism, inhibiting its function.
• Vupanorsen is an investigational antisense therapy by Pfizer for potential SHTG. Vupanorsen acts through a novel mechanism, targeting ANGPTL3, a genetically validated target of lipoprotein metabolism. Vupanorsen was developed using Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform. In a Phase 2a study, vupanorsen met the primary endpoint of significant reductions in TG levels and multiple secondary endpoints compared to placebo, with a favorable safety and tolerability profile.

Severe Hypertriglyceridemia Overview
Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to an increased risk of cardiovascular disease (CVD).

For further information, refer to the detailed Severe Hypertriglyceridemia Unmet Needs, Severe Hypertriglyceridemia Market Drivers, and Severe Hypertriglyceridemia Market Barriers, click here for Severe Hypertriglyceridemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Emerging Drugs Profile
• ARO-APOC3: Arrowhead Pharmaceuticals
• Olezarsen: Ionis Pharmaceuticals

Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
There are approx. 10+ Severe Hypertriglyceridemia companies are developing Severe Hypertriglyceridemia therapies. The Severe Hypertriglyceridemia companies which have their Severe Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals, Inc.

Request a sample and discover the recent advances in Severe Hypertriglyceridemia Ongoing Clinical Trial Analysis and Medications, click here @ Severe Hypertriglyceridemia Treatment Landscape- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
• Severe Hypertriglyceridemia Assessment by Product Type
• Severe Hypertriglyceridemia by Stage and Product Type
• Severe Hypertriglyceridemia Assessment by Route of Administration
• Severe Hypertriglyceridemia by Stage and Route of Administration
• Severe Hypertriglyceridemia Assessment by Molecule Type
• Severe Hypertriglyceridemia by Stage and Molecule Type

Some of the companies in the Severe Hypertriglyceridemia Therapeutics Market include-
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others

Dive deep into rich insights for drugs for the Severe Hypertriglyceridemia Pipeline, click here @ Severe Hypertriglyceridemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Severe Hypertriglyceridemia Pipeline Report
• Coverage- Global
• Severe Hypertriglyceridemia Companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
• Severe Hypertriglyceridemia Pipeline Therapies- Pegozafermin, Olezarsen, Ethyl Icosapentate, K-877, Fenofibrate, omefas, CaPre, and others
• Severe Hypertriglyceridemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Severe Hypertriglyceridemia Mergers and acquisitions, Severe Hypertriglyceridemia Licensing Activities @ Severe Hypertriglyceridemia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Severe Hypertriglyceridemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Severe Hypertriglyceridemia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Olezarsen: Ionis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ARO-APOC3: Arrowhead Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Severe Hypertriglyceridemia Key Companies
21. Severe Hypertriglyceridemia Key Products
22. Severe Hypertriglyceridemia- Unmet Needs
23. Severe Hypertriglyceridemia- Market Drivers and Barriers
24. Severe Hypertriglyceridemia- Future Perspectives and Conclusion
25. Severe Hypertriglyceridemia Analyst Views
26. Severe Hypertriglyceridemia Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.